The Board of Directors of Glenmark Pharmaceuticals, an integrated research-based pharmaceutical company, announced interim dividend of 65 per cent on eqiuty shares and 10.5 per cent on Redeemable Cumulative Preference shares for the year 2003-04.

The company has established strong position in dermatology, internal medicine, gynaecology, paediatric and ENT therapeutic segments in India.

Currently, it is exporting its products over 40 diferent countries across Africa, Asia Russia and now planning to entered into regulated markets in a big way. The company launched 18 new products during 2002-03 and acquired GlaxoSmithKlines’ manufacturing facility at Ankleshwar for the manufacture of API to the regulated markets.

The company is expected to maintain a growth of 30 per cent in the unregulated markets in the current year.